The Proteasome Inhibitor Bortezomib Controls Indoleamine 2,3-Dioxygenase 1 Breakdown and Restores Immune Regulation in Autoimmune Diabetes

Bortezomib (BTZ) is a first-in-class proteasome inhibitor approved for the therapy of multiple myeloma that also displays unique regulatory activities on immune cells. The enzyme indoleamine 2,3-dioxygenase 1 (IDO1) is a tryptophan metabolizing enzyme exerting potent immunoregulatory effects when ex...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Front Immunol
Главные авторы: Mondanelli, Giada, Albini, Elisa, Pallotta, Maria T., Volpi, Claudia, Chatenoud, Lucienne, Kuhn, Chantal, Fallarino, Francesca, Matino, Davide, Belladonna, Maria L., Bianchi, Roberta, Vacca, Carmine, Bicciato, Silvio, Boon, Louis, Ricci, Giovanni, Grohmann, Ursula, Puccetti, Paolo, Orabona, Ciriana
Формат: Artigo
Язык:Inglês
Опубликовано: Frontiers Media S.A. 2017
Предметы:
Immunology
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5390013/
https://ncbi.nlm.nih.gov/pubmed/28450863
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2017.00428
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы